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Objectives


Review NIOSH listed hazardous drugs (HDs) requiring handling
precautions in hospital and community settings



Discuss the importance and highlight proper handling and
disposal of hazardous chemotherapy as outlined in USP <800>



Review counseling points for precautions and handling of oral
chemotherapy agents at home

Pre-Assessment Questions


True or False




True or False




Patients on oral chemotherapy do not need to wear gloves
during administration
Oral chemotherapy is safe to dispose in the everyday
trash, as long as it is in its original container

True or False


Precautions during every day handling are to protect the
hazardous drug, not the user

What is a Hazardous Drug (HD)?
Term first used by ASHP in 1990
 National Institute for Occupational Safety and Health
(NIOSH) definition:




Any drug (or active pharmaceutical ingredient) that is
identified as having ≥ 1 of the following:
• Carcinogenicity
• Teratogenicity (or developmental toxicity)
• Reproductive toxicity in humans
• Organ toxicity (at low doses in humans or animals)
• Genotoxicity
• Drug that mimics an existing hazardous drug in
structure or toxicity
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

Why do we care about HDs?


~8 million US healthcare workers are potentially
exposed to HDs






Contamination can occur during transport, compounding,
cleaning and administration
May lead to absorption by healthcare workers

Consider HD use at home causing contamination


Oral chemotherapy

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

Types of Exposure
Dermal contact and absorption
 Inhalation
 Injection
 Ingestion


NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

Patient Care Areas


Contamination also extends beyond the pharmacy
and into patient care areas




Not only patients in these areas

Avoiding surface contamination


Surface contamination has been definitively linked to hand
contamination

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

What are the potential risks?


Acute effects







Hair loss
Cardiac toxicity
Kidney damage
Hearing loss
Nausea
Rashes



Long term effects




Cancer
Reproductive outcomes
Infertility

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

Who is at risk?

USP <800> Inforgraphic
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

The Evolution of Safe Handling

The Oncology Nurse. 9 September 2019
Clin J Oncol Nurse. 2015; 20(4):377-384

NIOSH HD List

https://www.cdc.gov/niosh/docs/2016-161/default.html

NIOSH HD List


HDs are categorized into three groups:




Group 1: Antineoplastic drugs
Group 2: Non-antineoplastic drugs
Group 3: Reproductive risk



NIOSH notes that many drugs in group 1 and 2 also
carry reproductive risk



Document provides guidance for personal protective
equipment (PPE) and ventilated engineering controls
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

NIOSH HD List


Drugs with safe-handling guidelines from the
manufacturer are automatically put on the list



NIOSH internal committee performs an initial review
of all new FDA drug approvals and new warnings on
existing drugs for a 2-year period



This is followed by an expert panel that reviews the
proposals (additions or deletions)

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

NIOSH HD List

https://www.cdc.gov/niosh/docs/2016-161/default.html

NIOSH Recommendations


Each organization should create its own list of drugs
considered to be hazardous, based on drugs in its
formulary



Primarily because reliance on lists of HDs provided
by NIOSH quickly becomes outdated


If you use a drug that is not included in the list, check the
available literature to see whether the unlisted drug
should be treated as a HD

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016

Handling and Disposal in
Healthcare settings

United States Pharmacopeia (USP)


USP is the only independent, not-for-profit,
nongovernmental pharmacopeia in the world


Develop and revise standards
• Standards are enforceable by the FDA and state boards
of pharmacy
• Identity, strength, quality and purity




Medicines
Food ingredients
Dietary supplements

https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare

United States Pharmacopeia (USP)


Important chapters to know about










USP <795>
• Non-sterile compounding
USP <797>
• Sterile compounding
USP <800>
• HD handling in healthcare settings
USP <825>
• Compounding radiopharmaceutical drugs

Revisions for <795> and <797> have been released

USP <800>


Describes the practice & quality standards for
handling HDs



Philosophy: no acceptable level of exposure to HDs
Purpose is to promote the protection of:
• Patients
• Healthcare worker safety
• Environment

Applies to all healthcare personnel who handle HDs
and all entities that store, prepare, transport, or
administer them
 Introduces element of containment


USP Compounding Expert Committee. USP General Chapter <800>

USP <800>


Management of HDs must include:







A list of HDs
Facility and engineering controls
Competent personnel
Safe work practices
Proper use of personal protective equipment (PPE)
Policies for HD waste segregation and disposal

USP Compounding Expert Committee. USP General Chapter <800>

Maintain a HD List


Must use NIOSH list as a basis



Agents on the NIOSH list that must follow USP <800>





Other agents on the NIOSH list





HD active pharmaceutical ingredients
All antineoplastics that require manipulation
Perform risk assessment
If no risk assessment performed, must handle as
hazardous and according to USP <800> requirements

Entity must review their list at least every 12 months
USP Compounding Expert Committee. USP General Chapter <800>

Assessment of Risk


Consider the following:








Category of HD based on NIOSH
Dosage form
Risk of exposure
Packaging
Any manipulation that might be required

Examples of assessments of risk can be found online


National Community Pharmacy Association

USP Compounding Expert Committee. USP General Chapter <800>
P Kienle and K Douglas. Perform an assessment of risk to comply with USP <800>

Facilities


Restrict access to areas where HDs are handled




Designated areas must be available for:







Protects persons not involved in HD handling

Receipt and unpacking
Storage of HDs
Nonsterile HD compounding (if performed by the entity)
Sterile HD compounding (if performed by the entity)

Also use dedicated equipment


Ex: designated counting tray for HDs
USP Compounding Expert Committee. USP General Chapter <800>

Receipt & Storage


Antineoplastic HDs and all HD APIs must be
unpacked in an area that is neutral/normal or
negative pressure




Do not unpack in sterile compounding areas or in positive
pressure areas

HDs and APIs requiring manipulation must be stored
separately from non hazardous medications in an
externally ventilated, negative-pressure room with at
least 12 air changes per hour (ACPH)

USP Compounding Expert Committee. USP General Chapter <800>

Engineering Controls


Required to protect the preparation from crosscontamination and microbial contamination (if
sterile compounding)



Engineering controls for containment




Primary
Secondary
Supplemental

USP Compounding Expert Committee. USP General Chapter <800>

Engineering Controls


Containment primary engineering control (C-PEC)




Ventilated device designed to minimize worker and
environmental HD exposure
Required:
• Class II Biological Safety Cabinets (BSC)


OR

• Compounding Aseptic Containment Isolator (CACI)

USP Compounding Expert Committee. USP General Chapter <800>

Class II BSCs

https://www.nuaire.com/how-class-two-bsc-work

CACI


Compounding aseptic containment isolator (CACI)

https://www.nuaire.com/how-class-two-bsc-work

Engineering Controls


Containment secondary engineering control (C-SEC)


The room in which the C-PEC is placed, which must:
• Be externally vented
• Be physically separated (i.e., a different room from
other preparation areas)
• Have an appropriate air exchange (e.g., ACPH)
• Have a negative pressure

USP Compounding Expert Committee. USP General Chapter <800>

Engineering Controls


Supplemental engineering controls


Closed system transfer devices (CSTD)
• MUST be used when administering antineoplastic HDs
when the dosage form allows


Not mandated for use in compounding

• CSTDs known to be physically or chemically
incompatible with a specific HD must not be used for
that HD

USP Compounding Expert Committee. USP General Chapter <800>

Personal Protective Equipment (PPE)
Provides worker protection to reduce exposure to
hazardous drug (HD) aerosols and residues
 Appropriate PPE must be worn when handling HDs,
including during:











Receipt
Storage
Transport
Compounding (sterile & nonsterile)
Administration
Deactivation/decontamination, cleaning and disinfecting
Spill control
Waste disposal
USP Compounding Expert Committee. USP General Chapter <800>

Chemotherapy Gloves
Must meet American Society for Testing and Materials
(ASTM) standard D6978
 Should be worn when handling all HDs




Including non-antineoplastics & for reproductive risk HDs

Must be powder free
 Inspect prior to use
 When used for sterile compounding, outer gloves
must be sterile
 Should be changed every 30 minutes unless otherwise
recommended by the manufacturer


USP Compounding Expert Committee. USP General Chapter <800>

Chemotherapy Gloves

Chemotherapy Gowns
Must be disposable and shown to resist permeability
 Must close in the back, be long sleeved, and have
closed cuffs that are elastic or knit
 Lab coats, scrubs or other absorbent materials are
not appropriate
 Potentially contaminated clothing must not be taken
home under any circumstance


USP Compounding Expert Committee. USP General Chapter <800>

Head, Hair, Shoe and Sleeve Covers


Provide protection from contact with HD residue



When compounding HDs, a 2nd pair of show covers
must be donned before entering the cleanroom and
doffed when exiting



Shoe covers worn in HD handling areas must not be
worn to other areas

USP Compounding Expert Committee. USP General Chapter <800>

Eye and Face Protection


Appropriate eye and face protection must be worn
when there is a risk for spills or splashes of HD




Administration in the surgical suite or cleaning a spill

Goggles & face shields

USP Compounding Expert Committee. USP General Chapter <800>

Personal Protective Equipment (PPE)

Disposal of Used PPE


Consider all PPE worn when handling HDs
contaminated



Place them in appropriate waste container per local,
state, and federal regulations

USP Compounding Expert Committee. USP General Chapter <800>

Personal Protective Equipment

Smith A. USP <800> What you need to know. Illinois Pharmacy Association
USP Compounding Expert Committee. USP General Chapter <800>

Disposal


All personnel who perform routine custodial waste
removal/cleaning activities in HD handling areas




Must be trained in appropriate procedures!
• To protect themselves and the environment

Disposal of all HD waste (including unused HDs and
trace-contaminated PPE) must comply with all
applicable federal, state, and local regulations

USP Compounding Expert Committee. USP General Chapter <800>

Disposal of
HDs

What about cleaning?


Must establish written procedures for
decontamination, deactivation and cleaning




Must wear appropriate PPE




For sterile compounding, also disinfection

2 pairs of gloves and impermeable disposable gowns

Wet wipe approach

USP Compounding Expert Committee. USP General Chapter <800>

4 Step Cleaning Process


All areas and reusable equipment where HDs are
handled must be deactivated/decontaminated &
cleaned

Cleaning Step
Deactivation

Purpose

Example Agents

Render compound inert or
inactive

•

Sodium hypochlorite or
EPA registered oxidizer
Peroxide formulations

•

Decontamination

Remove HD residue

•
•
•
•

Sterile alcohol
Sterile water
Peroxide
Sodium hypochlorite

Cleaning

Remove organic and
inorganic material

•

Germicidal detergent

Disinfection

Destroy microorganisms

•

Sterile alcohol and/or
EPA-registered
disinfectant

USP Compounding Expert Committee. USP General Chapter <800>

Deactivation & Decontamination


Carefully selected agent





Hazardous byproducts
Respiratory effects
• Some solutions may require the addition of respiratory
protection
Caustic damage to surfaces
• Sodium hypochlorite causes corrosion


MUST be neutralized with sodium thiosulfate or by following
with another agent (ex: sterile alcohol) to remove it

Deactivator

Decontaminator
USP Compounding Expert Committee. USP General Chapter <800>

Cleaning & Disinfecting
 Cleaning



Removal of contaminants and HD residue
Detergents or solvents

 Disinfection




Kills microorganisms
Used after cleaning
Sterile compounding areas
Cleaner & Disinfectant

USP Compounding Expert Committee. USP General Chapter <800>

Spills


MUST be contained and cleaned immediately




By qualified personnel with appropriate PPE

Facility dependent processes


Must have a clear policy and checklist
• Document competence of personnel, circumstances
and management of spills



Spill kits
Respirators (if too large for a spill kit)

USP Compounding Expert Committee. USP General Chapter <800>

Spill Kit Example

Oral Chemotherapy Handling and
Disposal

Oral Chemotherapy


Traditional oral chemotherapy agents available since
1950s



Prescriptions of oral chemotherapy are becoming
more common



Make up around 25% of the oncology market



Convenient but not just any pill


Still requires extra caution
Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know

Oral Chemotherapy

https://www.dana-farber.org/chemotherapy/oral-chemotherapy/

Safe Handling at Home


Principles of safe handling










Keep in original container
Storage
• Store in a cool, dry place and away from sunlight
• Safe space away from children and pets
Wash hands before and after handling
Do not crush, break or chew
Stay consistent with administration
Do not dispose in the toilet or in the garbage

Incorporate these key items in your counseling
https://www.dana-farber.org/chemotherapy/oral-chemotherapy/

Wearing Gloves at Home


Gloves help protect caregivers from absorbing
chemotherapy through the skin





Some package inserts recommend gloves to be used
Should be worn any time chemotherapy is handled by
someone other than the patient

Patients do not need to wear gloves when taking
their medication


Washing hands thoroughly before and after handling will
help minimize exposure to other household members

https://www.dana-farber.org/chemotherapy/oral-chemotherapy/

Don’t Forget!


Topical Chemotherapy





Applied to the skin
Cream, gel, or ointment
Example: 5-fluorouracil
Consider recommending the use of gloves when applying
topical agents

Oral/Topical Chemotherapy Disposal


Improper disposal pollutes the water and ground
and is toxic to plants, animals and humans



Only a few drug manufacturers provide instructions
on oral chemotherapy disposal


Celgene, the maker of lenalidomide, thalidomide, and
pomalidomide provides patients with packaging material
to return unused medications

Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know

Oral/Topical Chemotherapy Disposal


Most cities have a hazardous waste disposal policy
that patients can follow




Most fire/police stations and retail pharmacies will not
dispose of oral chemotherapy

Different options for patients




Contact dispensing pharmacy for disposal
Hazardous waste pick up through state of Florida
Drug take back site or program

Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know

Oral/Topical Chemotherapy Disposal
Drug take back site or program
 Patients can locate an authorized collection location
in their area online




https://apps2.deadiversion.usdoj.gov/pubdispsearch/sprin
g/main?execution=e1s1

Association of Community Cancer Centers. Oral chemotherapy: what your patients need to know

Oral/Topical Chemotherapy Disposal

https://apps2.deadiversion.usdoj.gov/pubdispsearch/spring/main?execution=e1s1

DEA National Drug Take-Back Day
April 25, 2020
 Liquid medications and IV medications are not
accepted
 Results of October 2019






Total Law Enforcement Participation: 4,896
Total Collection Sites: 6,174
Total Weight Collected: 882,919 lbs. (441.5 Tons)

https://www.oncolink.org/blogs/2019/10/tomorrow-is-national-prescription-drug-take-back%E2%80%8B-day/

Assessment Questions


True or False




True or False




Patients on oral chemotherapy do not need to wear gloves
during administration
Oral chemotherapy is safe to dispose in the everyday
trash, as long as it is in its original container

True or False


Precautions during every day handling are to protect the
hazardous drug, not the user

Assessment Questions


True or False




True or False




Patients on oral chemotherapy do not need to wear gloves
during administration
Oral chemotherapy is safe to dispose in the everyday
trash, as long as it is in its original container

True or False


Precautions during every day handling are to protect the
hazardous drug, not the user

Assessment Questions


True or False




True or False




Patients on oral chemotherapy do not need to wear gloves
during administration
Oral chemotherapy is safe to dispose in the everyday
trash, as long as it is in its original container

True or False


Precautions during every day handling are to protect the
hazardous drug, not the user

Assessment Questions


True or False




True or False




Patients on oral chemotherapy do not need to wear gloves
during administration
Oral chemotherapy is safe to dispose in the everyday
trash, as long as it is in its original container

True or False


Precautions during every day handling are to protect the
hazardous drug, not the user

Thank You!

Questions?
Email: paulams@baptisthealth.net
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Florida State Board of Pharmacy Laws
Effective: 08/19/2019
 64B16-27.797 The Standards of Practice for
Compounding Sterile Products










Beginning on October 1, 2014, all sterile compounding
shall be performed in accordance with the minimum
practice and quality standards of the following chapters of
the United States Pharmacopeia (USP):
(a) Chapter 797, Pharmaceutical Compounding-Sterile
Preparations;
(b) Chapter 71, Sterility Tests;
(c) Chapter 85, Bacterial Endotoxins Test;
(d) Chapter 731, Loss on Drying.

